Plasminogen Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F

The Global Plasminogen Market is projected to expand from USD 2.79 Billion in 2025 to USD 3.83 Billion by 2031, reflecting a CAGR of 5.42%. Plasminogen is a glycoprotein zymogen that converts to plasmin, an enzyme vital for fibrinolysis and wound healing, with the market focusing primarily on therapeutic concentrates for treating congenital Type I plasminogen deficiency and ligneous conjunctivitis. Market growth is chiefly driven by the enhanced identification of rare coagulation disorders through advanced genetic screening and the increasing regulatory approval of specific replacement therapies. These fundamental medical necessities create a sustainable demand foundation that is distinct from transient market trends.

However, the sector faces a substantial challenge regarding the limited supply of source plasma and the high capital barriers associated with fractionation, which restricts the number of capable manufacturers. This consolidation results in low supply elasticity and sustains high therapy costs. According to the 'Plasma Protein Therapeutics Association', in '2024', member companies produced over 60 percent of the plasma protein therapies used worldwide. This centralized production capacity underscores a supply chain vulnerability that creates risks of shortages and may impede broader market expansion and accessibility.

Market Driver

The primary forces propelling the global plasminogen market are regulatory approvals for novel replacement therapies and the strategic expansion of manufacturing infrastructure. The transition from compounding pharmacy formulations to FDA-approved biologicals requires immense capital investment in fractionation facilities to ensure a consistent supply. A pivotal development occurred when, according to a November 2024 corporate press release by Kedrion Biopharma, the U.S. FDA approved the company's manufacturing facility in Bolognana, Italy, to produce Ryplazim. This milestone allows for production scaling to meet global demand, overcoming supply bottlenecks. The high barriers to entry are evidenced by the financial scale required; according to Kedrion Biopharma's 'Annual Report 2023' released in April 2024, the company generated revenues of 1.4 billion Euro, highlighting the consolidated nature of players capable of sustaining such specialized operations.

Simultaneously, the expansion of clinical indications in ophthalmology is acting as a critical catalyst for increasing patient diagnosis. Ligneous conjunctivitis is often the sentinel symptom leading to the identification of the underlying congenital deficiency. According to the 'Ryplazim Now Available in US' announcement by Kedrion Biopharma in May 2024, approximately 81 percent of patients with congenital plasminogen deficiency develop lesions on one or both eyes as their lead symptom. By focusing on this clinical presentation, clinicians are narrowing the diagnostic gap, accelerating patient identification, and establishing a clear medical necessity that drives insurance reimbursement and consistent market uptake for lifelong replacement therapies.

Market Challenge

The Global Plasminogen Market faces a substantial obstacle due to the finite supply of source plasma and the intense capital requirements for fractionation. These barriers effectively limit the number of capable manufacturers, leading to a consolidated market structure where supply cannot easily adjust to rising demand. This rigidity creates low supply elasticity, maintaining high costs for therapies and restricting accessibility for patients, particularly in regions without established domestic collection capabilities.

This concentration of production and collection infrastructure introduces critical vulnerabilities into the supply chain. The market's growth is directly hampered by the geographic imbalance of plasma availability, which limits the volume of raw material available for processing. According to the 'Plasma Protein Therapeutics Association' in '2024', member companies operated approximately 160 plasma donation centers in the European Union. This relatively low number of local collection points in a major market underscores the heavy reliance on imported plasma, which creates logistical bottlenecks. Consequently, the inability to rapidly scale raw material collection in diverse regions serves as a hard ceiling on the industry's expansion potential.

Market Trends

The expansion of clinical applications into Diabetic Foot Ulcer and Wound Care Management represents a transformative shift for the Global Plasminogen Market, moving the industry beyond its traditional focus on rare congenital deficiencies toward high-volume chronic indications. Manufacturers are increasingly leveraging the pro-inflammatory and immunoregulatory properties of plasminogen to develop regenerative therapies for non-healing wounds, a segment with a substantially larger addressable patient population than Type I deficiency. Validating this commercial trajectory, according to Omnio AB's May 2025 press release 'Omnio raises €4.3 Million to accelerate wound-healing drug to clinical stage', the company secured €4.3 million to finalize GMP manufacturing and advance its recombinant plasminogen candidate into clinical trials specifically for chronic wound management.

Simultaneously, the establishment of cross-border partnerships for expanded commercial distribution is reshaping the market's logistical framework to overcome the accessibility barriers inherent to rare disease therapies. As production consolidates among a limited number of global fractionators, companies are forging strategic alliances with specialized distributors to ensure consistent product availability across international jurisdictions. Exemplifying this trend, according to the 'Kedrion Expands Ryplazim Distribution Network' announcement by Kedrion Biopharma in March 2025, the company integrated three major specialty pharmacy partners, including CuraScript SD and CVS Health, into its United States network to optimize patient access to its plasminogen replacement therapy.

Key Market Players

• Boehringer Ingelheim Inc. GmbH
• Kedrion S.p.A
• Genentech
• Prometic Life Sciences Inc
• Grifols, S.A
• Octapharma AG
• Green Cross Corporation
• Baxter International Inc.
• CSL Behring LLC
• Renaissance Acquisition Holdings LLC

Report Scope

In this report, the Global Plasminogen Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasminogen Market, By Type

• Intravenous Injection
• Eye Drops

Plasminogen Market, By Application

• Ligneous Conjunctivitis
• Diabetic Foot
• Wound Healing
• Others

Plasminogen Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasminogen Market.

Available Customizations:

Global Plasminogen Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).